Litcius/Paper detail

Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial

Farid Boulad, Aurelio Maggio, Xiuyan Wang, Paolo Moi, Santina Acuto, Friederike Kogel, Chayamon Takpradit, Susan E. Prockop, Jorge Mansilla‐Soto, Annalisa Cabriolu, Ashlesha Odak, Jinrong Qu, Keyur Thummar, Fang Du, Lingbo Shen, Simona Raso, Rita Barone, Rosario Di Maggio, Lorella Pitrolo, Antonino Giambona, Maura Mingoia, J.K. Everett, Pascha Hokama, Aoife M. Roche, Adrian Cantu, Hriju Adhikari, Shantan Reddy, Eric E. Bouhassira, Narla Mohandas, Frederic D. Bushman, Isabelle Rivière, Michel Sadelain

2022Nature Medicine47 citationsDOIOpen Access PDF

Topics & Concepts

Genetic enhancementMedicineViral vectorStem cellCD34Progenitor cellHaematopoiesisThalassemiaImmunologyGlobinBiologyCancer researchInternal medicineHemoglobinGeneticsGeneRecombinant DNAVirus-based gene therapy researchHemoglobinopathies and Related DisordersParvovirus B19 Infection Studies
Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial | Litcius